PATENT CLAIM ANALYSIS

Application Number: 16066427
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "234200"]

Abstract:
The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.

Claim (Index 14):
The method according to  claim 13 , wherein the disease, disorder or condition is at least one proliferative disease selected from the group consisting of non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, prostate cancer, bladder cancer, liver cancer, skin cancer, glioma, breast cancer, melanoma, glioblastoma, rhabdomyosarcoma, ovarian cancer, astrocytoma, Ewing's sarcoma, retinoblastoma, epithelial cell carcinoma, colon cancer, kidney cancer, gastrointestinal stromal tumor, leukemia, histiocytic lymphoma, nasopharyngeal carcinoma, or combinations thereof.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 94.0
- Lexical Diversity: 1.71429
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16062399', '13319079', '15534838', '14521766', '15544676']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8445035175826628
- 35 USC 102 Novelty (BERT): 0.589416537768921
- Combined Prediction Score: 0.8189948196012886
- Mean Citation Score: 419.36657
- Max Citation Score: 604.61755
- Similarity Product: 407.3530277446688

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test